Abiraterone
(asked on 5th September 2017) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, if he will make Zytiga available on the NHS.
This question was answered on 13th September 2017
The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance recommending Zytiga (abiraterone) for the treatment of metastatic prostate cancer subject to a commercial access arrangement agreed between the manufacturer and NHS England.
National Health Service commissioners in England are legally required to fund drugs and treatments recommended in NICE technology appraisal guidance. This is reflected in the NHS Constitution as a right to NICE approved drugs.